SCHEMBL21019272

SCHEMBL21019272

c1ccc(-c2ccc(N(c3ccc(-c4ccccc4)cc3)c3cc4oc5ccc6oc7ccccc7c6c5c4c4ccccc34)cc2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PLA2G2A P14555 5/20 0.39
▸ PLA2G4A P47712 5/20 0.39
▸ TNKS O95271 2/20 0.35
▸ HPGD P15428 3/20 0.35
▸ SMN1; SMN2 Q16637 3/20 0.35
▸ NPC1 O15118 3/20 0.35
▸ RAB9A P51151 3/20 0.35
▸ CYP3A4 P08684 2/20 0.35
▸ ABCG2 Q9UNQ0 2/20 0.35
▸ GABRP O00591 1/20 0.35
▸ GABRD O14764 1/20 0.35
▸ CA12 O43570 1/20 0.35
▸ CA1 P00915 1/20 0.35
▸ CA2 P00918 1/20 0.35
▸ TP53 P04637 1/20 0.35
▸ ABCB1 P08183 1/20 0.35
▸ PARP1 P09874 1/20 0.35
▸ ADORA3 P0DMS8 1/20 0.35
▸ AR P10275 1/20 0.35
▸ CYP19A1 P11511 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21019271 0.99 PLA2G2A (0.38) PLA2G2APLA2G4ATNKSHPGDSMN1; SMN2
SCHEMBL22739399 0.96 PLA2G2A (0.35) PLA2G2APLA2G4ATNKSHPGDSMN1; SMN2
SCHEMBL21019687 0.95 PLA2G2A (0.36) PLA2G2APLA2G4ATNKSHPGDSMN1; SMN2
SCHEMBL25869328 0.94 PLA2G2A (0.38) PLA2G2APLA2G4ATNKSHPGDSMN1; SMN2
SCHEMBL25869742 0.93 PLA2G2A (0.37) PLA2G2APLA2G4ATNKSHPGDSMN1; SMN2
SCHEMBL15852275 0.93 CCNC (0.36) PLA2G2APLA2G4ATNKSHPGDSMN1; SMN2
SCHEMBL21019520 0.91 KDM4E (0.38) HPGDSMN1; SMN2NPC1RAB9ACYP3A4
SCHEMBL15852267 0.91 CCNC (0.35) PLA2G2APLA2G4ATNKSHPGDSMN1; SMN2
SCHEMBL21019280 0.90 PLA2G2A (0.34) PLA2G2APLA2G4ATNKSHPGDSMN1; SMN2
SCHEMBL21019279 0.90 PLA2G2A (0.34) PLA2G2APLA2G4ATNKSHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10995098-B2 Heterocyclic compound and organic light emitting device comprising the same LG CHEM, LTD. (KR) 2021-05-04 — — US disclosed
US-20190152985-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING THE SAME LG CHEM, LTD. (KR) 2019-05-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190152985-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING THE SAME CRY1, CYP1A1, CYP1B1 PLA2G2A 3733/4885PLA2G4A 3887/4885TNKS 1701/4885
US-10995098-B2 Heterocyclic compound and organic light emitting device comprising the same CRY1, CYP1A1, CYP1B1 PLA2G2A 3733/4885PLA2G4A 3887/4885TNKS 1701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback